NRL’s extensive portfolio—encompassing immunohistochemistry, tumor biomarker profiling, HER2 and hormone receptor analysis, and genomic testing—demonstrates its commitment to advancing diagnostic accuracy.
Through this global exchange of expertise, NRL continues to champion innovation, collaboration, and excellence in breast pathology and cancer diagnostics across the region.